mTOR-targeted therapy of cancer with rapamycin derivatives.

By S. Vignot, S. Faivre, D. Aguirre, E. Raymond. Annals of Oncology, 2005

639 citations recorded by the source corpus.

Subfields: Immunology, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/595729c075af7244c9112614d5e143f703b6895e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. Guido Kroemer
2. Michael N. Hall
3. L. Zitvogel

In Molecular Biology

1. Michael N. Hall
2. R. Loewith
3. Guido Kroemer
4. S. Wullschleger
5. David M. Sabatini
6. K. Guan
7. L. Galluzzi
8. Asier González González

Citations in the corpus

• Efficacy and Safety of Sirolimus in the Treatment of Complicated Vascular Anomalies (2016, neutral): “CR 0 0 PR 47 (83) [70–95] 45 (85) [73–97] PD 7 (12) [2–23] 8 (15) [3–27] SD 3 (5) [0–13] 0”
• TOR signaling in growth and metabolism. (2006, result): “Clinical trial results show that mTOR inhibitors are generally well tolerated and may induce prolonged stable disease and even tumor regressions in a subset of patients (Dancey, 2005; Vignot et al., 2005).”
• Current development of mTOR inhibitors as anticancer agents (2006, background): “Three major signalling pathways that have been identified as important in cancer include the phosphatidylinositol 3-kinase (PI3K)/AKT kinase cascad”